SCHEMBL3339784

SCHEMBL3339784

CCn1c(=O)c(Br)cc2c(C)nc(Nc3ccc(-n4ccnc4)cc3)nc21

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.58
ALDH1A1 P00352 1/20 0.58
GLA P06280 1/20 0.58
GAA P10253 1/20 0.58
HPGD P15428 1/20 0.58
MAPK1 P28482 1/20 0.58
HTT P42858 1/20 0.58
HSD17B10 Q99714 1/20 0.58
RXFP1 Q9HBX9 1/20 0.58
CDK4 P11802 3/20 0.41
CCND1 P24385 3/20 0.41
CCND2 P30279 3/20 0.41
CCND3 P30281 3/20 0.41
PIK3CA P42336 4/20 0.40
JAK3 P52333 1/20 0.37
ACVR1 Q04771 1/20 0.37
FGFR1 P11362 2/20 0.36
EGFR P00533 2/20 0.36
PDE3B Q13370 2/20 0.36
PDE3A Q14432 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3336744 0.84 CDK4 (0.53) CDK4CCND1CCND2CCND3JAK3
SCHEMBL3339232 0.83 PIK3CA (0.58) KDM4EALDH1A1GLAGAAHPGD
SCHEMBL189479 0.83 ALDH1A1 (0.66) KDM4EALDH1A1GLAGAAHPGD
SCHEMBL189237 0.82 HSD17B10 (0.69) KDM4EALDH1A1GLAGAAHPGD
SCHEMBL190014 0.81 KDM4E (0.58) KDM4EALDH1A1GLAGAAHPGD
SCHEMBL188921 0.81 MAPK1 (0.58) KDM4EALDH1A1GLAGAAHPGD
SCHEMBL189169 0.81 KDM4E (0.58) KDM4EALDH1A1GLAGAAHPGD
SCHEMBL189897 0.80 KDM4E (0.57) KDM4EALDH1A1GLAGAAHPGD
SCHEMBL4225915 0.77 KDM4E (0.58) KDM4EALDH1A1GLAGAAHPGD
SCHEMBL188366 0.76 MAPK1 (0.52) KDM4EALDH1A1GLAGAAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100150827-A1 PYRIDO [2, 3-D] PYRIMIDIN-7-ONE COMPOUNDS AS INHIBITORS OF P13K-ALPHA FOR THE TREATMENT OF CANCER EXELIXIS, INC (US) 2010-06-17 US claimed
EP-2142543-B1 PYRIDO [2, 3-D]PYRIMIDIN-7-ONE COMPOUNDS AS INHIBITORS OF PI3K-ALPHA FOR THE TREATMENT OF CANCER EXELIXIS INC (US) 2013-05-22 EP disclosed
US-20100150827-A1 PYRIDO [2, 3-D] PYRIMIDIN-7-ONE COMPOUNDS AS INHIBITORS OF P13K-ALPHA FOR THE TREATMENT OF CANCER EXELIXIS, INC (US) 2010-06-17 US disclosed
US-20100150827-A1 PYRIDO [2, 3-D] PYRIMIDIN-7-ONE COMPOUNDS AS INHIBITORS OF P13K-ALPHA FOR THE TREATMENT OF CANCER EXELIXIS, INC (US) 2010-06-17 US disclosed
US-20100150827-A1 PYRIDO [2, 3-D] PYRIMIDIN-7-ONE COMPOUNDS AS INHIBITORS OF P13K-ALPHA FOR THE TREATMENT OF CANCER EXELIXIS, INC (US) 2010-06-17 US disclosed
EP-2142543-A1 PYRIDO [2, 3-D]PYRIMIDIN-7-ONE COMPOUNDS AS INHIBITORS OF PI3K-ALPHA FOR THE TREATMENT OF CANCER Exelixis, Inc. (US) 2010-01-13 EP disclosed
WO-2008127678-A1 PYRIDO [2, 3-D] PYRIMIDIN-7-ONE COMPOUNDS AS INHIBITORS OF PI3K-ALPHA FOR THE TREATMENT OF CANCER EXELIXIS, INC. (US) 2008-10-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100150827-A1 PYRIDO [2, 3-D] PYRIMIDIN-7-ONE COMPOUNDS AS INHIBITORS OF P13K-ALPHA FOR THE TREATMENT OF CANCER PIK3CA, CDKN1A, PIK3CD KDM4E 865/4885ALDH1A1 2333/4885GLA 3062/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.